Plate Nº 97 · recorded October 30, 2026
Health & Medicine ResearchReported finding
Gamma Delta T Cells: The Immune Weapon That Sees Through Lung Cancer
WEHI scientists found gamma delta T cells that destroy disguised small cell lung cancer cells, with two approved drugs boosting the effect in lab tests.
By Nathan Brooks3 min read682 words
In brief
- Fewer than 7% of small cell lung cancer patients survive five years after diagnosis.
- The study, led by WEHI, was published in Cancer Cell on October 22, 2026.
- Gamma delta T cells destroyed SCLC cells in lab-grown mini tumors, even when tumors evaded conventional immune cells.
- Two approved drugs, tarlatamab and zoledronate, substantially boosted the cells' cancer-killing ability in lab experiments.
- The investigation drew on data from the IMpower133 and CASPIAN immunotherapy trials.

Fewer than 7% of small cell lung cancer patients survive five years after diagnosis — but researchers have now found an overlooked immune cell that can attack the disease even when it hides from conventional defenses.
The discovery, published October 22, 2026, in the journal Cancer Cell, comes from scientists at the Walter and Eliza Hall Institute (WEHI) in Melbourne. The cells in question are called gamma delta T cells — a less-studied branch of the immune system's T cell family. Unlike conventional T cells, they can recognize tumors that have disguised themselves from immune surveillance, one of the biggest obstacles in treating this cancer.
"For decades, we've known that small cell lung cancer is exceptionally good at hiding from the immune system," said Professor Kate Sutherland, the study's senior author and a laboratory head at WEHI. "We've found an immune cell that appears to be able to see through that disguise."
Why does this cancer resist treatment?
Small cell lung cancer (SCLC) is the most aggressive form of lung cancer worldwide. Immunotherapy has transformed care for several cancer types, yet only a small proportion of SCLC patients see lasting benefits. The reason: SCLC tumors frequently dodge the conventional immune cells that most immunotherapies depend on.
The WEHI team's data suggest a way around that problem. Patients whose tumors carried more gamma delta T cells tended to survive longer and showed stronger responses to immunotherapy. Sutherland called it "the strongest evidence yet that gamma delta T cells are present in small cell lung cancers and appear capable of fighting the disease."
How did the researchers test it?
The scientists built miniature tumors — called "mini tumors" — in the lab from tissue samples donated by patients, obtained through the Victorian Cancer Biobank in partnership with the Royal Melbourne Hospital. These models rank among the most realistic laboratory versions of SCLC created so far.
The team then introduced gamma delta T cells taken from the same patients' blood. The results were striking: the immune cells proved highly effective at identifying and destroying SCLC cells.
The researchers went one step further and tested two already-approved drugs:
- Zoledronate, approved for osteoporosis and cancer-related bone disease, increased the number of available gamma delta T cells and sharpened their ability to spot the tumors.
- Tarlatamab, a cancer treatment already approved for SCLC, acted as a bridge — bringing immune cells and cancer cells together and directing the attack.
Used together, the two drugs substantially boosted the cells' cancer-killing power in laboratory experiments.
What could this mean for patients?
Dr. Jin Ng, the study's first author, said the findings could support a treatment approach called adoptive cell transfer. That means collecting a patient's immune cells, multiplying them outside the body, and reinfusing large numbers of them to fight the cancer.
Because methods for expanding and reinfusing gamma delta T cells already exist, the path to the clinic may be shorter than usual. "For patients with lower gamma delta T cell levels, therapies such as zoledronate may offer a way to boost their cancer-fighting immune cells," Ng said. "This could open an entirely new avenue for personalized treatment approaches in small cell lung cancer and other solid cancers."
It's worth keeping the caveats in view. So far, the killing experiments happened in laboratory tumor models, not in patients. The survival link between cell numbers and outcomes shows correlation, not proven causation.
Where did the investigation start?
The study began with a re-analysis of two major clinical trials, IMpower133 and CASPIAN, which established immunotherapy as a standard SCLC treatment. WEHI's genomics and bioinformatics teams spotted gamma delta T cell signatures in the trial data — and found that patients with stronger signatures were among those who benefited most from immunotherapy.
The WEHI team is now collaborating with scientists at the Doherty Institute to turn the discovery into a new class of immunotherapy drugs. The research was supported by Cancer Council Victoria, the National Health and Medical Research Council, The CASS Foundation, and the International Association for the Study of Lung Cancer.
via dx.doi.org (Original)
More from Nathan Brooks
Show full bio
Market editor covering companies, deals and strategy in general science news at SciBeat.
456 articles
Nearby plates
- Immune Cells Blur the Line Between Innate and Adaptive Defenses
- Researchers identify MEK as driver of T cell exhaustion in cancer
- Aging and sex shape cancer immunity, new study suggests
- New Drug CS18 Reverses Cancer Treatment Resistance in Lab Tests
- Blocking a Metabolic Weak Point May Reactivate Tired Immune Cells